New aromatase inhibitors: More selectivity, less toxicity, unfortunately, the same activity

European Journal of Cancer Part A

Volumn 32, Issue 3, 1996, Pages 393-395

  Castiglione Gertsch, M ^a  

^a SIAK Coordinating Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; FADROZOLE; FORMESTANE; LETROZOLE; TAMOXIFEN; VOROZOLE;

ARTICLE; BREAST CANCER; HOT FLUSH; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LETHARGY; PRIORITY JOURNAL; RASH; THROMBOSIS; VERTIGO;

EID: 0029886489     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00013-5     Document Type: Editorial

References (19)

1. Beatson GT On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases Lancet 2 1896 104 107
2. Beatson GT On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases Lancet 2 1896 162 165
3. Marshall FHA Jolly WA Contributions to the physiology of mammalian reproduction Phil Trans R Soc B198 1906 99 141
4. van Landeghem AAJ Poortman J Nabuurs M Thijssen JHH Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue Cancer Res 45 1985 2900 2906
5. Edery M Goussard J Dehennin L Endogenous oestradiol 17β concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content Ear J Cancer 17 1981 115
6. Flamm Honig S Treatment of metastatic disease. Hormonal therapy and chemotherapy Harris JR Lippman ME Morrow M Hellman S Diseases of the Breast 1996 Lippincott-Raven Philadelphia 685
7. Wiseman LR McTavish D Formestane: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer Drugs 45 1993 66 84
8. Wouters W DeCoster R Goeminne N Beerens D van Dun J Aromatase inhibition by the antifungal ketokonazole J Ster Biochem 30 1988 387 389
9. Raats JI Falkson G Falkson HC A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer J Clin Oncol 10 1992 111 116
10. Thürlimann B Beretta K Bacchi M For the Swiss Group for Clinical Cancer Research (SAKK). First line fadrozole HCI (COS 16949A) versus Tamoxifen (TAM) in advanced breast cancer: prospective randomized study SAKK 20/88 Proc Ann Meet Am Soc Clin Oncol 14 1995 A90
11. Goss PE Clark RM Ambus U Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen Clin Cancer Res 1 3 1995 287 294
12. Jonat W Howell A Blomqvist C A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer Eur J Cancer 32A 1996 404 412
13. Lubet RA Steele VE Casebolt TL Eto I Kelloff GJ Grubbs CJ Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats Carcinogenesis 15 1994 2775 2780
14. Brufman G Biran S Second line hormonal therapy with aminoglutethimide in metastatic breast cancer Ana Oncol 29 1990 717 720
15. Coombes RC Stein RC Aromatase inhibitors in human breast cancer Proc R Doc Edinburgh 95B 1989 283 291
16. Höffken K Jonat W Possinger K Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study J Clin Oncol 8 1990 875 880
17. Perez-Carrion R Alberola-Candel V Calabresi F Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer Ann Oncol 5 1994 19 24 (suppl)
18. Vinholes J Paridaens R Piccart MJ An EORTC breast group phase II study of vorozole (R 83842), a new aromatase inhibitor in advanced breast cancer Proc Ann Meet Am Soc Clin Oncol 13 1994 A223
19. Lipton A Demers LM Harvey HA Letrozole (CGS 20267): a phase I study of a new potent oral aromatase inhibitor of breast cancer Cancer 75 1995 2132 2138